Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06136884 |
| Title | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | A2A Pharmaceuticals Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Karmanos Cancer Institute | RECRUITING | Detroit | Michigan | 48201 | United States | Details |
| Oklahoma Univeristy | RECRUITING | Oklahoma City | Oklahoma | 73104 | United States | Details |
| Mary Crowley Cancer Research | RECRUITING | Dallas | Texas | 75230 | United States | Details |
| The University of Texas M.D. Anderson Cancer Center | RECRUITING | Houston | Texas | 77030 | United States | Details |
| Next Oncology -Virginia | RECRUITING | Fairfax | Virginia | 22031 | United States | Details |